The antispasmodic agent flopropione inhibits cutaneous overactive TRPV3 channels and may hold repurposing potential for the prevention or therapy of TRPV3-related skin diseases such as dermatitis and chronic pruritus. This evidence concerns the gene TRPV3 and skin disorder.